64
Participants
Start Date
March 1, 2025
Primary Completion Date
November 10, 2027
Study Completion Date
July 10, 2028
mFOLFOX6 + dabrafenib and cetuximab or panitumumab in the first line of therapy
Dabrafenib 150 mg twice orally daily Cetuximab 500 mg/m2 (120-minute IV infusion) every two weeks or Panitumumab 6 mg/kg (60-minute IV infusion) every two weeks Oxaliplatin 85 mg/m2 (120-minute IV infusion) every two weeks, Сalcium folinate 400 mg/m2 (120-minute IV infusion) every two weeks 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours every two weeks.
RECRUITING
Blokhin's Russian Cancer Research Center, Moscow
City Clinical Oncology Hospital No 1
OTHER_GOV
Moscow City Oncology Hospital No. 62
OTHER_GOV
The Loginov MCSC MHD
UNKNOWN
MMCC Kommunarka MHD
UNKNOWN
Blokhin's Russian Cancer Research Center
OTHER